Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Human Papilloma Virus Vaccine Effective In Women Aged 24-45 Not Previously Exposed
An article published Online First and in an upcoming edition of The Lancet reports that women aged between 24 and 45 can be protected by the human papilloma virus (HPV) vaccine, if they have not been already infected by the virus. The report is the work of Dr Nubia Mu÷±oz, from the National Institute of Cancer, Bogot÷ˇ, Colombia, and collaborators.
generic viagra online
International Action Needed To Combat Epidemic Of Noncommunicable Diseases
IDF, WHF and UICC join forces
News of the day
U.S. Food And Drug Administration Approves ONGLYZA™ (saxagliptin) For The Treatment Of Type 2 Diabetes Mellitus In Adults
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) approved ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor. ONGLYZA is indicated as an adjunct to diet and exercise to improve blood sugar (glycemic) control in adults for the treatment of type 2 diabetes mellitus. ONGLYZA once daily can be used in combination with commonly prescribed oral anti-diabetic medications - metformin, sulfonylureas or thiazolidinediones (TZD) - or as a monotherapy to significantly reduce glycosylated hemoglobin (A1C) levels. ONGLYZA should not be used for the treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis (high levels of certain acids, known as ketones, in the blood or urine). ONGLYZA has not been studied in combination with insulin.
Cardiovascular

House Panel Passes Protection For Drug Makers

The House Energy and Commerce Committee passed an amendment to their broad health reform bill giving drug makers 12 years of exclusive rights to market new biologic drugs, "a setback" to the administration and consumer advocates who hoped to make generic drugs more widely available, the Wall Street Journal reports. The panel voted 47-11 on the measure, which "would also allow "evergreening," the practice by pharmaceutical companies of making minimal adjustments to their drugs, such as creating extended-release versions, as a way to lengthen their monopoly." "Mr. Obama and some Democrats, including the energy committee chairman, Rep. Henry Waxman, D-Calif., have pushed for getting generic versions of complex biologic drugs to the market in five to seven years, saying it would speed up access for consumers to cheaper generic brands and help reduce the country"s health-care costs," the Journal reports (Mundy, 8/1). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009